Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | MAP3K14 | Q99558 | 3/20 | 0.40 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.36 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22462862 | 1.00 | GPR119 (0.41) | GPR119USP30MAP3K14ALDH2KMT2A | |
| SCHEMBL22462783 | 0.86 | AR (0.40) | GPR119USP30ALDH2KMT2ARORC | |
| SCHEMBL30272618 | 0.86 | AR (0.40) | GPR119USP30ALDH2KMT2ARORC | |
| SCHEMBL22462777 | 0.83 | KDM1A (0.37) | KMT2APDK2 | |
| SCHEMBL28868627 | 0.77 | GPR119 (0.38) | GPR119USP30ALDH2KMT2ARORC | |
| SCHEMBL23091733 | 0.76 | EPHX2 (0.51) | GPR119KMT2AEPHX2 | |
| SCHEMBL29693489 | 0.76 | EPHX2 (0.51) | GPR119KMT2AEPHX2 | |
| SCHEMBL21722989 | 0.75 | STS (0.43) | GPR119USP30ALDH2KMT2ARORC | |
| SCHEMBL25263787 | 0.74 | RORC (0.42) | GPR119USP30ALDH2KMT2ARORC | |
| SCHEMBL31455360 | 0.73 | MAPT (0.50) | GPR119ALDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2026-01-22 | — | — | US | disclosed |
| US-12281124-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4474017-A2 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| EP-3837263-B1 | NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2024-07-03 | — | — | EP | disclosed |
| US-20240150373-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-11802133-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230050901-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-02-16 | — | — | US | disclosed |
| EP-4028402-A1 | RADIOLABELED COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2022-07-20 | — | — | EP | disclosed |
| US-20220202963-A1 | RADIOLABELED COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2022-06-30 | — | — | US | disclosed |
| CN-114650994-A | Radiolabelled compounds | 豪夫迈·罗氏有限公司 | 2022-06-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022130-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LIPA, LPL | GPR119 192/4885USP30 986/4885MAP3K14 3903/4885 |
| US-12281124-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | LIPC, LPL, MGLL | GPR119 53/4885USP30 1173/4885MAP3K14 3237/4885 |
| US-20240150373-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LPL, MGLL | GPR119 53/4885USP30 1173/4885MAP3K14 3237/4885 |
| US-11802133-B2 | Heterocyclic compounds as monoacylglycerol lipase inhibitors | LIPC, LPL, MGLL | GPR119 53/4885USP30 1173/4885MAP3K14 3237/4885 |
| US-20220202963-A1 | RADIOLABELED COMPOUNDS | MGLL, PNLIP, LPL | GPR119 128/4885USP30 1025/4885MAP3K14 2461/4885 |
| US-20230050901-A1 | HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS | LIPC, LPL, MGLL | GPR119 53/4885USP30 1173/4885MAP3K14 3237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.